Ranbaxy Laboratories is currently trading at Rs. 723.40, up by 19.75 points or 2.81% from its previous closing of Rs. 703.65 on the BSE.

The scrip opened at Rs. 706.25 and has touched a high and low of Rs. 728.00 and Rs. 706.25 respectively. So far 87423 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 724.95 on 28-Jan-2015 and a 52 week low of Rs. 308.00 on 04-Feb-2014.

Last one week high and low of the scrip stood at Rs. 728.00 and Rs. 684.00 respectively. The current market cap of the company is Rs. 30877.63 crore.

The promoters holding in the company stood at 63.22% while Institutions and Non-Institutions held 21.16% and 15.61% respectively.

US Federal Trade Commission (USFTC) has completed its review of the proposed acquisition of Ranbaxy Laboratories by Sun Pharmaceutical Industries and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). The early termination of the waiting period under the HSR Act satisfies one of the essential conditions to the closing of the Ranbaxy acquisition.

Sun Pharma and Ranbaxy also announced that the FTC accepted a proposed consent agreement pursuant to which, Sun Pharma and Ranbaxy have agreed to divest Ranbaxy’s interests in generic minocycline tablets and capsules to an external third party.

Sun Pharma and Ranbaxy are working closely towards completion of the transaction and will comply with the conditions laid down in the FTC consent agreement within the specified time.

 

Peers
Company Name CMP
Sun Pharma Inds. 1523.80
Dr. Reddys Lab 5959.10
Cipla 1352.95
Zydus Lifesciences 934.50
Lupin 1599.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.